References
- World Health Organization (WHO). Vaccinating against cervical cancer. Bull World Health Organ 2007;85:89-90.
- Parkin M, Bray F, Ferlay J, Global Cancer Statistics, 2002. CA Cancer J Clin 2005;55:74-108.
- Bosch FX, Lorincz A, Muñoz N, The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55: 244-265.
- Walboomers JM, Jacobs MV, Manos MM, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
- De Villiers EM, Fauquet C, Broker TR, Classifications of papillomaviruses. Virology 2004;324:17-27.
- Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006;61(6 Suppl 1):S3-14.
- Denny L, Kuhn L, De Souza M, Screen-and treat approaches for cervical cancer prevention in low-resource settings. JAMA 2005;294:2173-2181.
- Arbyn M, Raifu AO, Autier P, Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18:1708-1715.
- International Agency for Research on Cancer (IARC). IARC Handbook of Cancer Prevention. Volume 10, Cervix Cancer Screening.Lyon: IARC press, 2004.
- Hungarian National Cancer Control Programme (HNCCP). Available at: http://www.cancerworld.org/cancerworldadmin/getStaticModFile.aspx?id=1683. Accessed November 24, 2007.
- Boncz I, Sebestyén A, Döbrossy L, [The coverage of cervical screening in Hungary]. Orvosi Hetilap 2007;148:2177-2182.
- Trimble CL, Genkinger JM, Burke AE, Active and passive cigarette smoking and the risk of cervical neoplasia. Obstet Gynecol 2005;105:174-81.
- Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007;23:213-227.
- Kornya L, Cseh I, Deak J, The diagnostics and prevalence of genital human papillomavirus (HPV) infection in Hungary. Eur J Obstet Gynecol Reprod Biol 2002;100:231-236.
- Deák J, Cseh I, Szöllösi J, [Detection of human papilloma-virus infection by the nucleic acid hybridization method (a multicenter study)]. Orvosi Hetilap 1999;140:115-120.
- NIB Research. Nordic survey, Hungary 2004: Personal interview with 300 women (representative between the ages of 16-45). Unpublished Merck Sharp & Dohme survey, 2004. Data are available from MSD Hungary local database.
- National Health Insurance Fund Administration (NHIFA). http://www.oep.hu. Accessed November 28, 2007.
- European Agency for the Evaluation of Medicinal Products (EMEA). (2006) European Public Assessment Report (EPAR). Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/silgard/073206en6.pdf. Accessed October 30, 2007.
- Cutts FT, Franceschi S, Goldie S, Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007;85:719-726.
- Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28-41.
- Issues & Answers. Drivers and barriers to HPV vaccination among consumers in strategic Merck vaccine international Markets. Unpublished Merck Sharp & Dohme data. Apr/May 2004.
- Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007;27:414-422.
- Elbasha EH, Galvani. Vaccination against multiple HPV types. Math Biosci 2005;197:88-117.
- Insinga RP, Dasbach EJ, Elbasha EH, Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine 2007;26:128-139.
- Arbyn M, Raifu AO, Autier P, Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18:1708-15. Epub 2007 March 16.
- Muñoz N, Bosch FX, Castellsague X, Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285.
- Kulsingham SL, Benard D, Barnabas RV, Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008;6:4 [Epub ahead of print].
- Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008;14:244-251.
- Gulácsi L. The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience. Eur J Health Econ 2007;8:83-88.
- World Health Organization (WHO). Threshold values for intervention cost-effectiveness by region. Available at: http://www.who.int/choice/costs/CER_levels/en/index.html. Accessed November 20, 2007.
- Central Intelligence Agency. The World Factbook – Hungary. Available at: https://www.cia.gov/library/publications/the-world-factbook/print/hu.html. Accessed November 25, 2007.
- Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry. Tufts-New England Medical Center, ICRHPS, 2006. Available at: http://www.tufts-nemc.org/cearegistry/data/docs/PhaseIIIACompleteLeagueTable.pdf. Accessed November 26, 2007.
- Health Protection Agency. Diagnoses and rates of selected STIs seen at GUM clinics, United Kingdom: 2000-2004. National, Regional and Strategic Health Authority Summary Tables. Available at: http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/epidemiology/datatables2004.htm. Accessed September 09, 2007.
- Brown DR, Kjaer SK, Sigurdsson K, The Impact of quadrivalent human papillomavirus (HPV; 6, 11, 16, 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-935.
- Carter JJ, Madeleine MM, Shera K, Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001;61:1934-1340.
- Hobbs CG, Sterne JA, Bailey M, Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006;31:259-266.
- Freed GL, Derkay CS. Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int J Pediatr Otorhinolaryngol 2006;70:1799-1803.
- Ács N, Brandtmüller Á, Nagy L, Cost of cervix cancer treatment in Hungary. Eur J Health Econ 2006;7(Suppl 1) (Abstracts, 6th European Conference on Health Economics, 2006, 6-9 July, Budapest, Hungary)